Results 241 to 250 of about 33,791,512 (292)

Glucagon-like peptide-1 receptor agonists and rotator cuff disease: a scoping review. [PDF]

BMC Musculoskelet Disord
Duru DO, Zhou AK, Lee DKR, Carroll PJ, Elmaraghy A.   +4 more
europepmc   +1 more source

WITHDRAWN: Can glucagon like peptide-1 receptor agonists be beneficial for brain health?

Ballabio G, Mason A, Paz V, Dale C, Sofat R, Garfield V.   +5 more
europepmc   +1 more source

How glucagon-like is glucagon-like peptide-1? [PDF]

Diabetologia, 1984
Although glucagon-like peptide-1 has the appearance of a glucagon-homologue that may be co-secreted with glucagon, synthetic glucagon-like peptide-1-(1-37) does not significantly affect plasma glucose and insulin concentrations when administered at high doses (100 and 400 micrograms) to cortisone-pretreated rabbits.
L O Uttenthal, M Ghiglione
exaly   +3 more sources

Some of the next articles are maybe not open access.

Related searches:

Glucagon-like peptide-1 and glucagon-like peptide-2

Best Practice & Research Clinical Endocrinology & Metabolism, 2004
The glucagon-like peptides (glucagon-like peptide-1 (GLP-1) and glucagon-like peptide-2 (GLP-2)) are released from enteroendocrine cells in response to nutrient ingestion. GLP-1 enhances glucose-stimulated insulin secretion and inhibits glucagon secretion, gastric emptying and feeding. GLP-1 also has proliferative, neogenic and antiapoptotic effects on
Laurie L. Baggio, Daniel J. Drucker
openaire   +1 more source

Glucagon Like Peptide-1 and Atherosclerosis

Cardiovascular & Hematological Agents in Medicinal Chemistry, 2012
Patients with type 2 diabetes mellitus are at high risk for developing cardiovascular diseases. Traditional medicines for type 2 diabetes, such as sulfonylureas, pioglitazone, and insulin have glucose lowering effects; however, they also increase the frequency of hypoglycemia and/or body weight and thus may cancel out the benefits of glucose lowering ...
Tomoya, Mita, Hirotaka, Watada
openaire   +2 more sources

Metabolic Messengers: glucagon-like peptide 1

Nature Metabolism, 2021
Glucagon like peptide-1 (GLP-1), a peptide hormone from the intestinal tract, plays a central role in the coordination of postprandial glucose homeostasis through actions on insulin secretion, food intake and gut motility. GLP-1 forms the basis for a variety of current drugs for the treatment of type 2 diabetes and obesity, as well as new agents ...
Fiona M. Gribble, Frank Reimann
openaire   +2 more sources